natgillin/translations-raw huggingface dataset:
Systemic exposures (AUC) in rats and mice at the no-observed adverse effect levels in these studies were at least 7- and 49-fold higher, respectively, than in humans treated with Hirobriz Breezhaler once a day at a dose of 300 microgram.
Süsteemse ekspositsiooni (AUC) väärtused rottidel ja hiirtel, mis ei põhjustanud kõrvaltoimete teket nendes uuringutes, olid vastavalt vähemalt 7 ja 49 korda suuremad kui inimestel, kes said ravi Hirobriz Breezhaler'iga üks kord päevas annuses 300 mikrogrammi.
As with other inhalation therapy, administration of Hirobriz Breezhaler may result in paradoxical bronchospasm that may be life-threatening.
Nagu igasuguse inhaleeritava ravi puhul, võib Hirobriz Breezhaler'i manustamisel tekkida paradoksaalne bronhospasm, mis võib olla eluohtlik.
Hirobriz Breezhaler capsules must always be stored in the blister, and only removed immediately before use.
Hirobriz Breezhaler kapsleid tuleb alati hoida blistris ja eemaldada need blistrist alles vahetult enne kasutamist.
The mean of the maximum changes in blood glucose were similar between Hirobriz Breezhaler and placebo.
Vere glükoosisisalduse maksimaalsete muutuste keskmine oli sarnane Hirobriz Breezhaler'i ja platseebo puhul.
The magnitude of exposure increases due to interactions does not raise any safety concerns given the safety experience of treatment with Hirobriz Breezhaler in clinical studies of up to one year at doses up to twice the maximum recommended therapeutic dose.
Koostoimetest tingitud ekspositsiooni suurenemise ulatus ei tõstata ohutusalaseid küsimusi, kuna Hirobriz Breezhaler'i kasutamine kliinilistes uuringutes kuni ühe aasta vältel maksimaalsest soovitatavast terapeutilisest annusest kuni kaks korda suuremates annustes oli ohutu.
Hirobriz Breezhaler, administered once a day at doses of 150 and 300 microgram consistently provided clinically significant improvements in lung function (as measured by the forced expiratory volume in one second, FEV1) over 24 hours across a number of clinical pharmacodynamic and efficacy studies.
Hirobriz Breezhaler, mida manustati üks kord päevas annustes 150 ja 300 mikrogrammi, viis järjekindlalt kopsufunktsiooni kliiniliselt olulise paranemiseni (mida mõõdeti forsseeritud ekspiratoorse mahu järgi ühes sekundis, FEV1) 24 tunni jooksul mitmetes kliinilistes farmakodünaamika ja efektiivsuse uuringutes.
Hirobriz Breezhaler is a long-acting beta2-adrenergic agonist, which is only indicated for COPD and should not be used in asthma due to the absence of long-term outcome data in asthma.
Hirobriz Breezhaler on pikatoimeline beeta-2-adrenomimeetikum, mis on näidustatud ainult KOKi raviks ja seda ei tohi kasutada astma raviks, sest puuduvad andmed pikaajalise kasutamise kohta astma korral.
Hirobriz Breezhaler has no or negligible influence on the ability to drive and use machines.
Hirobriz Breezhaler ei mõjuta või mõjutab ebaoluliselt autojuhtimise ja masinate käsitsemise võimet.
How to store Hirobriz Breezhaler Contents of the pack and other information
Kuidas Hirobriz Breezhaler'it säilitada Pakendi sisu ja muu teave
As demonstrated in 605 patients with COPD in a 26-week, double-blind, placebo-controlled Phase III study, there was no clinically relevant difference in the development of arrhythmic events monitored over 24 hours, at baseline and up to 3 times during the 26-week treatment period, between patients receiving recommended doses of Hirobriz Breezhaler treatment and those patients who received placebo or treatment with tiotropium.
Nagu demonstreeriti 605 KOKihaige osalusega 26-nädalases, topeltpimedas, platseeboga kontrollitud III faasi uuringus, puudus kliiniliselt oluline erinevus arütmiate tekke osas 24 tunni jooksul, uuringu alguses ja kuni kolmel korral 26-nädalase raviperioodi jooksul Hirobriz Breezhaler'i soovitatud annustega ravi saanud ja platseebot või tiotroopiumravi saanud patsientide vahel.
In this pack, you will find an inhaler and capsules (in blister) that contain the medicine as inhalation powder.
Sellest pakendist leiate inhalaatori ja kapslid (blistrites), mis sisaldavad ravimit inhaleeritava pulbrina.
If paradoxical bronchospasm occurs Hirobriz Breezhaler should be discontinued immediately and alternative therapy substituted.
Paradoksaalse bronhospasmi tekkimisel tuleb Hirobriz Breezhaler'i kasutamine otsekohe lõpetada ja alustada alternatiivset ravi.
The European Medicines Agency has waived the obligation to submit the results of studies with Hirobriz Breezhaler in all subsets of the paediatric population in chronic obstructive pulmonary disease (COPD) (see section 4.2 for information on paediatric use).
Euroopa Ravimiamet ei kohusta esitama Hirobriz Breezhaler'iga läbi viidud uuringute tulemusei laste kõikide alarühmade kohta kroonilise obstruktiivse kopsuhaiguse (KOK) korral (teave lastel kasutamise kohta: vt lõik 4.2).
Although indacaterol did not affect general reproductive performance in a rat fertility study, a decrease in the number of pregnant F1 offspring was observed in the peri- and post-developmental rat study at an exposure 14-fold higher than in humans treated with Hirobriz Breezhaler.
Kuigi indakaterool ei mõjutanud üldist reproduktsioonivõimet rottidel läbi viidud fertiilsusuuringutes, täheldati Hirobriz Breezhaler'iga ravitud rottidel sünnieelse ja-järgse arengu uuringus F1 põlvkonna rottidel tiinete järeltulijate arvu langust 14 korda kõrgema ekspositsiooniga kui inimestel.
Hirobriz Breezhaler should not be used in conjunction with other long-acting beta2-adrenergic agonists or medicinal products containing long-acting beta2-adrenergic agonists.
Hirobriz Breezhaler'it ei tohi kasutada koos teiste pikatoimeliste beeta-2-adrenomimeetikumidega või ravimitega, mis sisaldavad pikatoimelisi beeta-2-adrenomimeetikume.
Hirobriz Breezhaler has not been investigated in patients with not well controlled diabetes mellitus.
Hirobriz Breezhaler'i kasutamist ei ole uuritud halvasti kontrollitud diabeediga patsientidel.
What Hirobriz Breezhaler is and what it is used for What you need to know before you use Hirobriz Breezhaler How to use Hirobriz Breezhaler Possible side effects
Mis ravim on Hirobriz Breezhaler ja milleks seda kasutatakse Mida on vaja teada enne Hirobriz Breezhaler'i kasutamist Kuidas Hirobriz Breezhaler'it kasutada Võimalikud kõrvaltoimed
The 24-hour bronchodilator effect of Hirobriz Breezhaler was maintained from the first dose throughout a one-year treatment period with no evidence of loss in efficacy (tachyphylaxis).
Hirobriz Breezhaler'i 24-tunnine bronhe lõõgastav toime püsis esimesest annusest kuni üheaastase raviperioodi lõpuni, ilma et oleks ilmnenud toime kadumist (tahhüfülaksia).
The inhalation of the content of one 300 microgram capsule once a day, using the Hirobriz Breezhaler inhaler has been shown to provide additional clinical benefit with regard to breathlessness, particularly for patients with severe COPD.
Ühe 300-mikrogrammise kapsli sisu inhaleerimisel üks kord päevas Hirobriz Breezhaler inhalaatorist on saadud täiendavat kliinilist kasu hingelduse leevendamisel, eriti raske KOKiga patsientidel.
What Hirobriz Breezhaler looks like and content of the pack In this pack, you will find an inhaler, together with capsules in blister.
Kuidas Hirobriz Breezhaler välja näeb ja pakendi sisu Sellest pakendist leiate inhalaatori ja kapslid blistrites.
Although no clinically relevant effect on the cardiovascular system is usually seen after the administration of Hirobriz Breezhaler at the recommended doses, as with other beta2-adrenergic agonists, indacaterol should be used with caution in patients with cardiovascular disorders (coronary artery disease, acute myocardial infarction, cardiac arrhythmias, hypertension), in patients with convulsive disorders or thyrotoxicosis, and in patients who are unusually responsive to beta2adrenergic agonists.
Kuigi Hirobriz Breezhaler'i soovitatavate annuste manustamise järgselt ei täheldata tavaliselt kliiniliselt olulist toimet kardiovaskulaarsüsteemile, tuleb indakaterooli sarnaselt teiste beeta-2-adrenomimeetikumidega kasutada ettevaatlikult patsientidel, kellel esinevad kardiovaskulaarsed haigused (koronaartõbi, äge müokardiinfarkt, südame rütmihäired, hüpertensioon), krambiseisundid või türeotoksikoos, ning samuti patsientidel, kes on ebatavaliselt tundlikud beeta-2-adrenomimeetikumide suhtes.
The capsules must be administered only using the Hirobriz Breezhaler inhaler (see section 6.6).
Kapslite manustamiseks tohib kasutada ainult Hirobriz Breezhaler inhalaatorit (vt lõik 6.6).
Upon initiation of treatment with Hirobriz Breezhaler plasma glucose should be monitored more closely in diabetic patients.
Hirobriz Breezhaler'iga ravi alustamise järgselt tuleb diabeetikutel hoolikamalt jälgida plasma glükoosisisaldust.
At 600 microgram once-daily, the safety profile of Hirobriz Breezhaler was overall similar to that of recommended doses.
600 mikrogrammi üks kord päevas annuse korral oli Hirobriz Breezhaler'i ohutusprofiil üldiselt sarnane soovitatud annuste puhul täheldatuga.
Your Hirobriz Breezhaler pack: Each Hirobriz Breezhaler pack contains: one Hirobriz Breezhaler inhaler one or more blister containing Hirobriz Breezhaler capsules to be used in the inhaler.
Hirobriz Breezhaler'i pakend: Igas Hirobriz Breezhaler'i pakendis sisaldub: üks Hirobriz Breezhaler inhalaator, üks või mitu inhalaatoris kasutatavaid Hirobriz Breezhaler kapsleid sisaldavat blistrit.
Hirobriz Breezhaler was shown to reduce lung hyperinflation, resulting in increased inspiratory capacity during exercise and at rest, compared to placebo.
Hirobriz Breezhaler vähendas kopsude hüperinflatsiooni, mille tulemusena suurenes inspiratoorne kapatsiteet vastavalt koormusel ja puhkeolekus võrreldes platseeboga.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Hirobriz Breezhaler therapy, taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Rinnaga toitmise katkestamine või ravi katkestamine/jätkamine, tuleb otsustada arvestades imetamise kasu lapsele ja ravi kasu naisele.
In the event of deterioration of COPD during treatment with Hirobriz Breezhaler, a reevaluation of the patient and of the COPD treatment regimen should be undertaken.
Kui ravi ajal Hirobriz Breezhaler'iga tekib KOKi süvenemine, tuleb patsiendi seisundit ja KOKi raviskeemi uuesti hinnata.
Therefore, long-acting beta2-adrenergic agonists such as Hirobriz Breezhaler should be used with caution in patients with known or suspected prolongation of the QT interval or treated with medicinal products affecting the QT interval.
Seega tuleb pikatoimelisi beeta-2-adrenomimeetikume kasutada ettevaatusega patsientidel, kellel esineb või kahtlustatakse QT-intervalli pikenemist või kes kasutavad QT-intervalli mõjutavaid ravimpreparaate.
How long to continue your treatment with Hirobriz Breezhaler Keep using your treatment with Hirobriz Breezhaler for as long as your doctor tells you.
Kui kaua tuleb jätkata ravi Hirobriz Breezhaler'iga Jätkake ravi Hirobriz Breezhaler'iga senikaua, kui arst soovitab.
At the recommended doses, the adverse reaction profile of Hirobriz Breezhaler in patients with COPD shows clinically insignificant systemic effects of beta2-adrenergic stimulation.
Soovitatud annuste puhul näitab Hirobriz Breezhaler'i kõrvaltoimete profiil KOKihaigetel kliiniliselt ebaolulisi süsteemseid toimeid seoses beeta-2-adrenergilise stimulatsiooniga.
Hirobriz Breezhaler contains lactose
Hirobriz Breezhaler sisaldab laktoosi
The Hirobriz Breezhaler inhaler provided with each new prescription should be used.
Kasutada tuleb iga uue retseptiga ette nähtud Hirobriz Breezhaler inhalaatorit.
The Hirobriz Breezhaler Phase III clinical development programme involved patients with a clinical diagnosis of moderate to severe COPD.
Hirobriz Breezhaler'i III faasi kliinilises arendusprogrammis osalesid patsiendid, kelle kliiniliseks diagnoosiks oli keskmise raskusega või raske KOK.
The recommended dose is the inhalation of the content of one 150 microgram capsule once a day, using the Hirobriz Breezhaler inhaler.
Soovitatavaks annuseks on ühe 150-mikrogrammise kapsli sisu inhalatsioon üks kord päevas Hirobriz Breezhaler inhalaatorist.
Immediate hypersensitivity reactions have been reported after administration of Hirobriz Breezhaler.
On teatatud kohestest ülitundlikkusreaktsioonidest pärast Hirobriz Breezhaler'i manustamist.
Other medicines and Hirobriz Breezhaler
Muud ravimid ja Hirobriz Breezhaler
During clinical studies, clinically notable changes in blood glucose were generally more frequent by 1-2% on Hirobriz Breezhaler at the recommended doses than on placebo.
Kliinilistes uuringutes esines Hirobriz Breezhaler'i soovitatavate annuste kasutamisel veresuhkru taseme kliiniliselt väljendunud muutusi üldiselt sagedamini (1...2% võrra) kui platseebo puhul.
Paediatric population There is no relevant use of Hirobriz Breezhaler in the paediatric population (under 18 years).
Puudub Hirobriz Breezhaler'i asjakohane kasutus lastel (vanuses alla 18 aasta).
Clinically relevant effects on prolongation of the QTc-interval have not been observed in clinical studies of Hirobriz Breezhaler at recommended therapeutic doses (see section 5.1).
Hirobriz Breezhaler'i kliinilistes uuringutes ei ole soovitatavate terapeutiliste annuste kasutamisel täheldatud kliiniliselt olulisi toimeid QTc-intervalli pikenemisele (vt lõik 5.1).
What Hirobriz Breezhaler contains - Each Hirobriz Breezhaler 150 microgram capsule contains 150 microgram indacaterol as indacaterol maleate.
Mida Hirobriz Breezhaler sisaldab - Iga Hirobriz Breezhaler 150-mikrogrammine kapsel sisaldab 150 mikrogrammi indakaterooli indakateroolmaleaadina.
• Only use the Hirobriz Breezhaler inhaler contained in this pack.
• Kasutage ainult selles pakendis sisalduvat Hirobriz Breezhaler inhalaatorit.
Always keep the Hirobriz Breezhaler inhaler and capsules in a dry place.
Hoidke Hirobriz Breezhaler inhalaatorit ja kapsleid alati kuivas kohas.
Hirobriz Breezhaler, administered once a day at doses of 150 microgram and 300 microgram, showed clinically meaningful improvements in lung function.
Hirobriz Breezhaler'i manustamine üks kord päevas annustes 150 ja 300 mikrogrammi viis kopsufunktsiooni kliiniliselt olulise paranemiseni.
Hirobriz Breezhaler 300 microgram capsules have a blue product code “IDL 300” printed above a blue bar and a blue company logo ( ) printed below the blue bar.
Hirobriz Breezhaler 300-mikrogrammistele kapslitele on trükitud sinises kirjas toote kood „IDL 300“ sinise joone kohale ja firma logo ( ) sinise joone alla.
What you need to know before you use Hirobriz Breezhaler
Mida on vaja teada enne Hirobriz Breezhaler'i kasutamist
Hirobriz Breezhaler capsules must not be swallowed.
Hirobriz Breezhaler kapsleid ei tohi alla neelata.
Hirobriz Breezhaler 150 microgram capsules have a black product code “IDL 150” printed above a black bar and a black company logo ( ) printed below the black bar.
Hirobriz Breezhaler 150-mikrogrammistele kapslitele on trükitud mustas kirjas toote kood „IDL 150“ musta joone kohale ja firma logo ( ) musta joone alla.
Only use the capsules with the inhaler provided in this pack (Hirobriz Breezhaler inhaler).
Kasutage kapsleid ainult koos selles pakendis oleva inhalaatoriga (Hirobriz Breezhaler inhalaator).
An increase in the daily dose of Hirobriz Breezhaler beyond the maximum dose of 300 microgram is not appropriate.
Hirobriz Breezhaler'i ööpäevast annust ei tohi suurendada üle maksimaalse annuse, milleks on 300 mikrogrammi.
Hirobriz Breezhaler contains the active substance indacaterol which belongs to a group of medicines called bronchodilators.
Hirobriz Breezhaler sisaldab toimeainena indakaterooli, mis kuulub bronhodilataatoriteks ehk bronhilõõgastiteks nimetatud ravimite rühma.
There are no data available for use of Hirobriz Breezhaler in patients with severe hepatic impairment.
Puuduvad andmed Hirobriz Breezhaler'i kasutamise kohta raske maksakahjustusega patsientidel.
Hirobriz Breezhaler is not indicated for the treatment of acute episodes of bronchospasm, i.e. as rescue therapy.
Hirobriz Breezhaler ei ole näidustatud ägedate bronhospasmi episoodide raviks, st hooravimina.
- Each Hirobriz Breezhaler 300 microgram capsule contains 300 microgram indacaterol as indacaterol maleate.
- Iga Hirobriz Breezhaler 300-mikrogrammine kapsel sisaldab 300 mikrogrammi indakaterooli indakateroolmaleaadina.
When you start a new pack, use the new Hirobriz Breezhaler inhaler that is supplied in the pack.
Kui alustate uue pakendi kasutamist, kasutage pakendis olevat uut Hirobriz Breezhaler inhalaatorit.
Only use the Hirobriz Breezhaler inhaler contained in this pack.
Kasutage ainult selles pakendis sisalduvat Hirobriz Breezhaler inhalaatorit.
The Hirobriz Breezhaler inhaler enables you to inhale the medicine contained in a capsule.
Hirobriz Breezhaler inhalaator võimaldab kapslis sisalduvat ravimit sisse hingata.
Carton containing 30 capsules and one Hirobriz Breezhaler inhaler.
Karbis on 30 kapslit ja üks Hirobriz Breezhaler inhalaator.
The Hirobriz Breezhaler inhaler enables you to inhale the medicine contained in an Hirobriz Breezhaler capsule.
Hirobriz Breezhaler inhalaator võimaldab sisse hingata Hirobriz Breezhaler kapslis sisalduvat ravimit.
Carton containing 10 capsules and one Hirobriz Breezhaler inhaler.
Karbis on 10 kapslit ja üks Hirobriz Breezhaler inhalaator.
You should not use Hirobriz Breezhaler unless your doctor tells you so.
Hirobriz Breezhaler'it tohib kasutada ainult juhul, kui arst seda soovitab.
What Hirobriz Breezhaler is and what it is used for
Mis ravim on Hirobriz Breezhaler ja milleks seda kasutatakse
Talk to your doctor or pharmacist before using Hirobriz Breezhaler if you have asthma (in this case you should not use Hirobriz Breezhaler).
Enne Hirobriz Breezhaler'i kasutamist pidage nõu oma arsti või apteekriga: kui teil on astma (sellisel juhul ei tohi Hirobriz Breezhaler'it kasutada); kui teil on probleeme südamega; kui teil on epilepsia; kui teil on probleeme kilpnäärmega (türeotoksikoos); kui teil on suhkurtõbi.
Hirobriz Breezhaler is used to make breathing easier for adult patients who have breathing difficulties due to a lung disease called chronic obstructive pulmonary disease (COPD).
Hirobriz Breezhaler'it kasutatakse hingamise kergemaks muutmiseks kroonilisest obstruktiivsest kopsuhaigusest (KOK) tingitud hingamisraskustega täiskasvanutel.
Hirobriz Breezhaler is a single-dose inhalation device.
Hirobriz Breezhaler on inhalatsiooniseade ühekordse annuse manustamiseks.
Driving and using machines It is unlikely that Hirobriz Breezhaler will affect your ability to drive and use machines.
On ebatõenäoline, et Hirobriz Breezhaler võiks mõjutada autojuhtimise ja masinatega töötamise võimet.
Always use the new Hirobriz Breezhaler inhaler that comes with your new pack.
Kasutage alati uut Hirobriz Breezhaler inhalaatorit, mis on uues pakendis.
Hirobriz Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD).
Hirobriz Breezhaler on näidustatud bronhe lõõgastavaks säilitusraviks hingamisteede obstruktsiooni korral kroonilise obstruktiivse kopsuhaigusega (KOK) täiskasvanud patsientidel.
Show the pack of Hirobriz Breezhaler.
Näidake Hirobriz Breezhaler'i pakendit.
Never wash the Hirobriz Breezhaler inhaler with water.
Ärge kunagi peske Hirobriz Breezhaler inhalaatorit veega.
Never place a Hirobriz Breezhaler capsule directly into the mouthpiece of the Hirobriz Breezhaler inhaler.
Ärge kunagi pange Hirobriz Breezhaler kapslit otse Hirobriz Breezhaler inhalaatori huulikusse.
Breezhaler capsules with any other inhaler, and do not use Hirobriz Breezhaler inhaler to take any other capsule medicine.
Hirobriz Breezhaler kapsleid üheski teises inhalaatoris, samuti ärge kasutage Hirobriz
Reports of hypersensitivity have been received from post-approval marketing experience in association with the use of Hirobriz Breezhaler.
Turuletulekujärgselt on teatatud Hirobriz Breezhaler'i kasutamisega seotud ülitundlikkusest.
If you forget to inhale a dose, inhale just one dose at the usual time the next day.
Kui te unustate Hirobriz Breezhaler'it kasutada Kui te unustate annuse sisse hingamata, hingake järgmisel päeval tavalisel ajal sisse vaid üks annus.
How much Hirobriz Breezhaler to use
Kui palju Hirobriz Breezhaler'it kasutada
What Hirobriz Breezhaler is used for
Milleks Hirobriz Breezhaler'it kasutatakse
Never take the Hirobriz Breezhaler inhaler apart.
Ärge kunagi võtke Hirobriz Breezhaler inhalaatorit osadeks lahti.
Do not swallow Hirobriz Breezhaler capsules.
Ärge neelake Hirobriz Breezhaler kapsleid.
Do not store the capsules in the Hirobriz Breezhaler inhaler.
Ärge hoidke kapsleid Hirobriz Breezhaler inhalaatoris.
How to use Hirobriz Breezhaler
Kuidas Hirobriz Breezhaler'it kasutada
Hirobriz Breezhaler inhaler
HIROBRIZ BREEZHALER INHALAATORI KASUTUSJUHEND
For inhalation use only.
Ainult inhalatsiooniks.
Hirobriz Breezhaler 150 microgram inhalation powder, hard capsules Hirobriz Breezhaler 300 microgram inhalation powder, hard capsules indacaterol
Hirobriz Breezhaler 150 mikrogrammi inhaleeritav pulber kõvakapslites Hirobriz Breezhaler 300 mikrogrammi inhaleeritav pulber kõvakapslites indakaterool (indacaterolum)
How to store Hirobriz Breezhaler
Kuidas Hirobriz Breezhaler'it säilitada
Hirobriz Breezhaler 300 microgram inhalation powder, hard capsules indacaterol
Hirobriz Breezhaler 300 mikrogrammi inhaleeritav pulber kõvakapslites indacaterolum
In particular, please tell your doctor if you are using: medicines for breathing problems that are similar to Hirobriz Breezhaler (i.e. medicines such as salmeterol and formoterol).
Hirobriz Breezhaler'iga sarnased ravimid (ravimid nagu salmeterool ja formoterool) hingamisprobleemide leevendamiseks.
Hirobriz Breezhaler 150 microgram inhalation powder, hard capsules indacaterol
Hirobriz Breezhaler 150 mikrogrammi inhaleeritav pulber kõvakapslites indacaterolum
Hirobriz Breezhaler 300 microgram inhalation powder, hard capsules
Hirobriz Breezhaler 300 mikrogrammi inhaleeritav pulber kõvakapslites
• When you start a new pack, only use the new Hirobriz Breezhaler inhaler that is supplied in the pack.
• Kui alustate ravimi kasutamist uuest pakendist, kasutage uut pakendis olevat Hirobriz
Hirobriz Breezhaler 150 microgram inhalation powder, hard capsules
Hirobriz Breezhaler 150 mikrogrammi inhaleeritav pulber kõvakapslites
During treatment with Hirobriz Breezhaler, Stop using the medicine and tell your doctor immediately if you get tightness of the chest, coughing, wheezing or breathlessness immediately after using the medicine.
Kui teil tekib vahetult pärast ravimi kasutamist rindkere pingsus, köha, vilisev hingamine või hingeldus, lõpetage otsekohe ravimi kasutamine ja teavitage sellest oma arsti.
What Hirobriz Breezhaler is
Mis ravim on Hirobriz Breezhaler
Inhaler base
Breezhaler inhalaator
700 micrograms
700 mikrogrammi Klaaskehasisene implantaat aplikaatoris.
Intravitreal implant in applicator Intravitreal use pouch (foil) 1 pouch with applicator system
1 kotike aplikaatorsüsteemiga
The company has presented data from both laboratory and field studies on the effectiveness of the vaccine against the two bacteria.
Tootja esitas nii labori- kui ka väliuuringute andmed, et tõendada vaktsiini efektiivsust nimetatud kahe bakteri vastu.
Sows that have been vaccinated according to this scheme before need a single revaccination two to four weeks before the expected farrowing date.
Selle skeemi kohaselt juba vaktsineeritud emised vajavad ühekordset revaktsineerimist 2-4 nädalat enne eeldatavat poegimiskuupäeva.
E. Coli and C. perfringens vaccine
E. Coli ja C. perfringens vaktsiin
Reduced activity and lack of appetite on the day of vaccination commonly occurs.
Sageli esinevad vaktsineerimispäeval aktiivsuse vähenemine ja isu puudumine.
This summary was last updated on 14 June 2012.
Kokkuvõtte viimane uuendus: 14/06/2012.
A sometimes painful and hard swelling up to 10 cm in diameter may be observed at the injection site for up to 25 days.
Mõnikord võib täheldada süstekohal kuni 25 päeva valulikku ning kõva turset läbimõõduga kuni 10 cm.
The withdrawal period for Porcilis ColiClos is zero days for pig meat.
Porcilis ColiClosi keeluaeg on sealiha puhul null päeva.